Physician profile
Daniel J Tulman
NPI 1508954611
$6,696.14
in general payments reported to CMS, 2019-2025
27 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $750 · 2021: $352 · 2022: $839 · 2023: $1,453 · 2024: $1,033 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Entertainment: $20.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.04 |
| Entertainment | $20.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,063.46 | 2019-2025 | Tryptyr, Precision7, Total30 |
| Johnson & Johnson Vision Care, INC. | $834.23 | 2019-2025 | Acuvue |
| Coopervision INC. | $668.18 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $628.74 | 2020-2024 | Cequa |
| Bausch & Lomb Americas INC. | $398.37 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $382.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $331.55 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $292.98 | 2023-2024 | Radius |
| Optos, INC. | $245.37 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Amgen INC. | $227.83 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $219.99 | 2019-2023 | |
| Dompe US, INC. | $192.62 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $188.04 | 2023 | Tepezza |
| Abbvie INC. | $157.30 | 2022-2025 | |
| Maculogix, INC. | $127.17 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $111.35 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.12 | 2019-2020 | |
| Harrow Eye, LLC | $102.17 | 2024-2025 | Vevye |
| Ivantis, INC | $88.23 | 2020 | |
| Topcon Healthcare, INC. | $81.41 | 2023 | |
| Lombart Brothers, INC. | $69.59 | 2019 | |
| Biotissue Holdings INC. | $67.88 | 2022-2024 | |
| Visioneering Technologies, INC. | $39.00 | 2019-2022 | |
| Shire North American Group INC | $24.29 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $17.77 | 2022 | |
| Kala Pharmaceuticals, INC. | $15.33 | 2021 | |
| Allergan, INC. | $15.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.